Exolitus

Exolitus is a private, pre-revenue biotech leveraging exosome technology for therapeutic and cosmetic applications. Its core focus is on harnessing extracellular vesicles, particularly exosomes, as natural delivery vehicles for bioactive molecules to create next-generation healthcare solutions. The company operates a dual business model, developing its own pipeline for conditions like cancer and cardiovascular disease while offering contract research services and tools to other scientists. With participation in EU-funded projects, Exolitus is positioning itself at the intersection of advanced drug delivery and cutting-edge cosmeceuticals.

Platform for the production, isolation, characterization, and application of exosomes (a type of extracellular vesicle) as natural nanocarriers for bioactive molecules (e.g., miRNAs, proteins) for therapeutic and cosmetic delivery.

Exolitus competes in a rapidly growing but crowded field. In therapeutics, competitors include Codiak BioSciences, Evox Therapeutics, and numerous other biotechs developing exosome platforms. In cosmeceuticals and research services, it faces competition from specialized CROs and ingredient suppliers. Differentiation will depend on proprietary production methods, IP, and specific cargo engineering capabilities.